Surgery—with or without postoperative radioiodine—is the standard of care for most patients
with differentiated thyroid carcinoma (DTC). Thyroid hormone replacement therapy is the …

Purpose This review focuses on post-operative thyroid hormone replacement and
thyrotropin suppression therapy in patients with differentiated thyroid cancer. Methods A …

Differentiated thyroid cancer is the most common form of thyroid cancer and its prognosis is
favourable in most cases. Suppression of thyroid stimulating hormone (TSH) by supra …

Published guidelines on the treatment of thyroid carcinoma support TSH suppressive
therapy as the standard of care for long-term follow-up after initial surgery and sequential …

The ideal therapy for differentiated thyroid cancer is uncertain. Although thyroid hormone
treatment is pivotal, the degree of thyrotropin (TSH) suppression that is required to prevent …

BACKGROUND. Long-term thyroid hormone (TH) therapy aiming at the suppression of
serum thyrotropin (TSH) has been traditionally used in the management of well differentiated …

Background: Despite clinical practice guidelines for the management of differentiated thyroid
cancer (DTC), there are no recommendations on the optimal serum thyrotropin (TSH) …

Background: Levothyroxine suppression of thyrotropin (TSH) is broadly applied to patients
with thyroid cancer despite lack of consensus on the optimal TSH concentration necessary …

Context: TSH suppression therapy has been used to decrease thyroid cancer recurrence.
However, validation of effects through studies providing a high level of evidence has been …

Risk assessment is the cornerstone of contemporary management of thyroid cancer.
Following thyroid surgery, an initial risk assessment of recurrence and disease-specific …